Susquehanna Fundamental Investments’s Esperion Therapeutics ESPR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-65,260	Closed	-$144K	–	1124
2024 Q4	$144K	Buy	+65,260	New	+$152K	﹤0.01%	1027
2024 Q2	–	Sell	-166,457	Closed	-$446K	–	955
2024 Q1	$446K	Buy	+166,457	New	+$404K	0.02%	489
2023 Q3	–	Sell	-41,809	Closed	-$58.1K	–	444
2023 Q2	$58.1K	Hold	41,809	–	–	﹤0.01%	619
2023 Q1	$66.5K	Sell	41,809 -28,907	-41%	-$149K	﹤0.01%	916
2022 Q4	$441K	Buy	+70,716	New	+$506K	0.01%	904
2021 Q3	–	Sell	-50,792	Closed	-$1.07M	–	1750
2021 Q2	$1.07M	Buy	50,792 +42,133	+487%	+$1.01M	0.02%	825
2021 Q1	$243K	Buy	+8,659	New	+$255K	﹤0.01%	1349

Other funds holding ESPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PCM

PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna Fundamental Investments's ESPR Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 65,260 shares — an estimated $144K sold.

Susquehanna Fundamental Investments first reported a position in ESPR in Q1 2021 and held it in 7 quarters. The position peaked at $1.07M in Q2 2021. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

Susquehanna Fundamental Investments reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 65,260 Esperion Therapeutics shares in Q1 2025, an estimated $144K.
Susquehanna Fundamental Investments first reported a position in Esperion Therapeutics in Q1 2021 and held it in 7 quarters.
Susquehanna Fundamental Investments's Esperion Therapeutics position peaked at $1.07M in Q2 2021.
186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.